Camden National Bank’s Novartis NVS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $10.7M | Sell |
70,211
-658
| -0.9% | -$101K | 1.45% | 27 |
|
|
2025
Q4 | $9.77M | Buy |
70,869
+247
| +0.3% | +$32.3K | 1.34% | 31 |
|
|
2025
Q3 | $9.06M | Sell |
70,622
-435
| -0.6% | -$53.1K | 1.27% | 35 |
|
|
2025
Q2 | $8.6M | Sell |
71,057
-1,251
| -2% | -$141K | 1.24% | 37 |
|
|
2025
Q1 | $8.06M | Sell |
72,308
-1,201
| -2% | -$128K | 1.2% | 40 |
|
|
2024
Q4 | $7.15M | Sell |
73,509
-429
| -0.6% | -$45.7K | 1.07% | 47 |
|
|
2024
Q3 | $8.5M | Sell |
73,938
-1,444
| -2% | -$164K | 1.22% | 41 |
|
|
2024
Q2 | $8.03M | Buy |
75,382
+10,290
| +16% | +$1.03M | 1.24% | 40 |
|
|
2024
Q1 | $6.3M | Sell |
65,092
-1,403
| -2% | -$144K | 1.11% | 43 |
|
|
2023
Q4 | $6.71M | Sell |
66,495
-541
| -0.8% | -$52.2K | 1.25% | 41 |
|
|
2023
Q3 | $6.83M | Sell |
67,036
-491
| -0.7% | -$49.8K | 1.4% | 35 |
|
|
2023
Q2 | $6.81M | Sell |
67,527
-1,174
| -2% | -$117K | 1.33% | 35 |
|
|
2023
Q1 | $6.32M | Buy |
68,701
+519
| +0.8% | +$45.3K | 1.28% | 37 |
|
|
2022
Q4 | $6.19M | Sell |
68,182
-261
| -0.4% | -$22K | 1.29% | 38 |
|
|
2022
Q3 | $5.2M | Buy |
68,443
+308
| +0.5% | +$25.5K | 1.16% | 43 |
|
|
2022
Q2 | $5.76M | Buy |
68,135
+1,724
| +3% | +$151K | 1.19% | 43 |
|
|
2022
Q1 | $5.83M | Buy |
66,411
+285
| +0.4% | +$24.7K | 1.06% | 47 |
|
|
2021
Q4 | $5.78M | Sell |
66,126
-488
| -0.7% | -$40.5K | 1.02% | 42 |
|
|
2021
Q3 | $5.45M | Buy |
66,614
+1,439
| +2% | +$129K | 1.05% | 44 |
|
|
2021
Q2 | $5.95M | Sell |
65,175
-614
| -0.9% | -$54.7K | 1.12% | 43 |
|
|
2021
Q1 | $5.62M | Sell |
65,789
-619
| -0.9% | -$55.5K | 1.12% | 44 |
|
|
2020
Q4 | $6.27M | Sell |
66,408
-2,528
| -4% | -$221K | 1.3% | 37 |
|
|
2020
Q3 | $6M | Buy |
68,936
+536
| +0.8% | +$46.4K | 1.32% | 33 |
|
|
2020
Q2 | $5.97M | Buy |
68,400
+167
| +0.2% | +$14.4K | 1.48% | 27 |
|
|
2020
Q1 | $5.63M | Sell |
68,233
-8,806
| -11% | -$786K | 1.53% | 32 |
|
|
2019
Q4 | $7.29M | Buy |
77,039
+2,619
| +4% | +$235K | 1.48% | 37 |
|
|
2019
Q3 | $6.47M | Buy |
74,420
+809
| +1% | +$72.6K | 1.41% | 39 |
|
|
2019
Q2 | $6.72M | Sell |
73,611
-7,899
| -10% | -$669K | 1.55% | 35 |
|
|
2019
Q1 | $7.02M | Buy |
81,510
+867
| +1% | +$69.6K | 1.7% | 33 |
|
|
2018
Q4 | $6.2M | Buy |
80,643
+4,249
| +6% | +$331K | 1.71% | 32 |
|
|
2018
Q3 | $5.9M | Buy |
76,394
+2,844
| +4% | +$210K | 1.45% | 38 |
|
|
2018
Q2 | $4.98M | Buy |
73,550
+7,350
| +11% | +$507K | 1.31% | 40 |
|
|
2018
Q1 | $4.8M | Buy |
66,200
+1,074
| +2% | +$81.8K | 1.39% | 35 |
|
|
2017
Q4 | $4.9M | Buy |
65,126
+1,055
| +2% | +$79.6K | 1.42% | 34 |
|
|
2017
Q3 | $4.93M | Buy |
64,071
+2,091
| +3% | +$158K | 1.46% | 36 |
|
|
2017
Q2 | $4.63M | Buy |
61,980
+5,326
| +9% | +$377K | 1.42% | 36 |
|
|
2017
Q1 | $3.77M | Buy |
56,654
+2,845
| +5% | +$190K | 1.16% | 40 |
|
|
2016
Q4 | $3.51M | Buy |
+53,809
| New | +$3.49M | 1.08% | 40 |
|
Other funds holding NVS
Camden National Bank's NVS Position: Q1 2026 in Review
Camden National Bank reduced its Novartis (NVS) stake by 0.93% in Q1 2026, selling an estimated $101K and leaving 70,211 shares worth $10.7M. The position accounts for 1.45% of the portfolio, ranked #27.
Camden National Bank first reported a position in NVS in Q4 2016 and has held it in 38 quarters since. 1,591 funds tracked by Wall St. Rank hold NVS as of Q1 2026.
- Camden National Bank held 70,211 shares of Novartis worth $10.7M as of Q1 2026.
- Camden National Bank sold 658 Novartis shares in Q1 2026, an estimated $101K.
- Novartis made up 1.45% of Camden National Bank's portfolio in Q1 2026, its #27 holding.
- Camden National Bank first reported a position in Novartis in Q4 2016 and has held it in 38 quarters since.
- 1,591 funds tracked by Wall St. Rank held Novartis as of Q1 2026.
Based on Camden National Bank's 13F filing for Q1 2026, filed 4 May 2026.